Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic study in young patients with chronic kidney disease stage G5 from unknown etiology. The GENSEN study design Estudio genético en pacientes jóvenes con enfermedad renal crónica avanzada de etiología no filiada. Diseño del estudio GENSEN

  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Quiroga, Borja|||0000-0001-5730-1929
  • García-Aznar, José M.
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Ortiz, Alberto|||0000-0002-9805-9523
  • de Sequera, Patricia|||0000-0001-7705-9228
Introduction: Chronic kidney disease (CKD) of unknown etiology is one of the main causes of renal replacement therapy in our environment. Previous studies in other territories suggest that hereditary diseases could be one of the potential causes of this pathology, especially in younger patients. The GENSEN study will evaluate the presence of pathogenic genetic variants in subjects who have developed CKD category G5 before the age of 46, of unknown etiology. Methods: Observational, prospective and multicenter study, which evaluates the diagnostic usefulness of massive high-throughput sequencing (HTS) directed at a set of genes, in identifying the cause of CKD. Patients from all over Spain will be included, from whom a blood or saliva sample will be extracted, subsequently analyzing a panel of 529 genes associated with hereditary kidney disease. This publication communicates the study protocol and design. Conclusion: The GENSEN study will allow to evaluate the diagnostic performance of a gene panel study in young subjects from our environment with the development of category G5 CKD without a clear cause. An etiological diagnosis would offer potential benefits for patients and relatives (targeted therapies, clinical trials, detection of extrarenal manifestations, evaluation of relatives for living kidney donation, estimation of the risk of recurrence in the kidney graft, genetic counseling, among others) and would allow genetic study to be brought closer to nephrology in our country.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Complement Mediated Endothelial Damage in Thrombotic Microangiopathies

  • Blasco Pelicano, Miquel|||0000-0003-0789-7992
  • Guillén-Olmos, Elena
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Palomo, Marta|||0000-0002-3261-6577
Thrombotic microangiopathies (TMA) constitute a group of different disorders that have a common underlying mechanism: the endothelial damage. These disorders may exhibit different mechanisms of endothelial injury depending on the pathological trigger. However, over the last decades, the potential role of the complement system (CS) has gained prominence in their pathogenesis. This is partly due to the great efficacy of complement-inhibitors in atypical hemolytic syndrome (aHUS), a TMA form where the primary defect is an alternative complement pathway dysregulation over endothelial cells (genetic and/or adquired). Complement involvement has also been demonstrated in other forms of TMA, such as thrombotic thrombocytopenic purpura (TTP) and in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS), as well as in secondary TMAs, in which complement activation occurs in the context of other diseases. However, at present, there is scarce evidence about the efficacy of complement-targeted therapies in these entities. The relationship between complement dysregulation and endothelial damage as the main causes of TMA will be reviewed here. Moreover, the different clinical trials evaluating the use of complement-inhibitors for the treatment of patients suffering from different TMA-associated disorders are summarized, as a clear example of the entry into a new era of personalized medicine in its management.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Antithrombotic and prohemorrhagic actions of different concentrations of apixaban in patients exposed to single and dual antiplatelet regimens

  • Martínez Sánchez, Julia
  • Castrillo, Leticia
  • Jerez, Didac
  • Torramade-Moix, Sergi|||0000-0003-4409-9607
  • Palomo, Marta|||0000-0002-3261-6577
  • Mendieta, Guiomar|||0000-0001-6652-9036
  • Zafar, M. Urooj
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Sánchez, Pablo|||0000-0003-2787-822X
  • Badimon, Juan Jose
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Escolar, Ginès
  • Roqué, Mercè
We evaluated modifications in the hemostatic balance of different concentrations of apixaban (APIX) in 25 healthy donors and 53 patients treated with aspirin (ASA, n = 21), ASA and clopidogrel (ASA + CLOPI, n = 11), or ASA and ticagrelor (ASA + TICA, n = 21). Blood samples from participants were spiked ex vivo with apixaban 0 (APIX0), 40 (APIX40), and 160 ng/mL (APIX160). We assessed the effects of APIX on (1) clot formation, by ROTEM thromboelastometry; (2) thrombin generation primed by platelets; and (3) platelet and fibrin interactions with a thrombogenic surface, in a microfluidic model with circulating blood. APIX caused dose-related prolongations of clotting time with minimal impact on other ROTEM parameters. Thrombin generation was significantly inhibited by APIX160, with ASA + TICA actions showing the strongest inhibition (p < 0.01 vs APIX0). Microfluidic studies showed that APIX160 was more potent at suppressing platelet and fibrin interactions (p < 0.001 vs. APIX0). APIX40 demonstrated a consistent antithrombotic action but with a favorable protective effect on the structural quality of fibrin. APIX potentiated the antithrombotic effects of current antiplatelet regimens. APIX at 40 ng/mL, enhanced the antithrombotic action of single or dual antiplatelet regimens but was more conservative for hemostasis than the 160 ng/mL concentration.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

T-TAs® 01 as a new tool for the evaluation of hemostasis in thrombocytopenic patients after platelet transfusion

  • Sanz, Cristina
  • Escolar, Ginès
  • Diaz-Ricart, Maribel|||0000-0003-1122-0052
  • Samanbar, Sahar
  • Piñeyroa, Juan A.
  • Moreno-Castaño, Ana Belén|||0000-0003-0338-7514
  • Pino, Marc
  • Torramadé-Moix, Sergi
  • Martínez Sánchez, Julia
  • Lozano, Miquel|||0000-0003-2593-833X
background - Current laboratory tests fail to evaluate the hemostatic function of platelets in patients with thrombocytopenia. We investigated the use of the Total Thrombus-Formation Analysis System (T-TAS® 01 [Fujimori Kogyo Co, Tokyo, Japan]) to evaluate hemostasis under conditions of experimental thrombocytopenia, and in patients before and after platelet transfusion. materials and methods - Specific T-TAS 01 chips, for thrombocytopenic conditions, were used. The area under the curve (AUC) and occlusion time (OT, min) were measured in: (i) experimentally induced thrombocytopenia (183±15 to 6.3±1.2×10 platelets/µL) in blood samples from healthy donors (No.=13), and (ii) blood from oncohematological thrombocytopenic patients (No.=48), before and after platelet transfusion. The influences of hematocrit and number of transfusions were analyzed in these patients. results - Progressive reductions of AUC and prolongations of OT related significantly to decreasing platelet counts (p<0.05 for all) in experimental thrombocytopenia. In samples from thrombocytopenic patients, platelet counts, AUC and OT were, respectively, 10.8±0.6×10/µL, 175.2±59, and 27.2±1 min before transfusion; and 22±1.5×10/µL, 400.8±83 and 22.9±1.5 min after platelet transfusion (p<0.01 for all). A hematocrit below 25% or exposure to ten or more previous platelet transfusions had a negative impact on the T-TAS 01 performance in patients. In vitro correction of the hematocrit improved the hemostatic response in thrombocytopenic patients. discussion - T-TAS 01 measurements were sensitive to low platelet counts in the experimental setting. The technology was sensitive to evaluate the hemostatic capacity of platelet transfusions. Exposure to multiple medications, repeated platelet transfusions and lower hematocrits may interfere with the hemostatic performance in oncohematological patients with thrombocytopenia.